文献速递重症综合管理与镇静镇痛心脑血管急症

α2受体激动剂用于机械通气神经重症患者镇静的系统评价

A Systematic Review of Alpha-2 Agonists for Sedation in Mechanically Ventilated Neurocritical Care Patients.
PubMed 文献 · Neurocrit Care · 2018-01-01
一句话结论系统评价显示右美托咪定用于神经重症机械通气患者非操作性镇静未出现严重失代偿性血流动力学紊乱,但现有研究对镇静及血流动力学辅助用药报告不足。

该系统评价检索EMBASE、MEDLINE和CENTRAL Cochrane数据库(截至2016年6月),纳入17项研究,全部报告右美托咪定使用,其中仅7项报告了主要结局指标(平均动脉压、颅内压、脑灌注压)。对颅内压、脑灌注压和平均动脉压的统计学显著变化结果不一,但未发现严重血流动力学紊乱的证据。研究显著受限于缺乏对镇静及血流动力学辅助用药的报告。基于有限数据,右美托咪定似乎不会导致严重的、未代偿的脑或全身血流动力学紊乱;作者建议验证一种有效且安全的药物,并报告给药策略、镇静方案使用、辅助干预措施及预先定义的不良事件。

要点

  • 纳入17项研究全部报告右美托咪定,仅7项报告主要结局(平均动脉压、颅内压、脑灌注压)。
  • 对颅内压、脑灌注压和平均动脉压的统计学显著变化结果不一,但未发现严重血流动力学紊乱的证据。
  • 研究显著受限于缺乏对镇静及血流动力学辅助用药的报告。
  • 基于有限数据,右美托咪定似乎不会导致严重的、未代偿的脑或全身血流动力学紊乱。
  • 作者建议验证一种有效且安全的药物,并报告给药策略、镇静方案使用、辅助干预措施及预先定义的不良事件。

适用人群与场景

  • 神经重症成人患者(年龄18岁及以上),接受机械通气,使用α2受体激动剂进行非操作性镇静。

研究设计与关键结果

  • 系统评价纳入17项研究,全部报告右美托咪定使用,仅7项报告主要结局指标(平均动脉压、颅内压、脑灌注压)。
  • 对颅内压、脑灌注压和平均动脉压的统计学显著变化结果不一,但未发现严重血流动力学紊乱的证据。
  • 研究显著受限于缺乏对镇静及血流动力学辅助用药的报告。
  • 基于有限数据,右美托咪定似乎不会导致严重的、未代偿的脑或全身血流动力学紊乱。

证据类型、等级与局限

  • 证据类型:系统评价,纳入随机对照试验、前瞻性和回顾性队列研究。
  • 局限:研究显著受限于缺乏对镇静及血流动力学辅助用药的报告。

对床旁实践的改变

  • 基于有限数据,右美托咪定似乎不会导致严重的、未代偿的脑或全身血流动力学紊乱。
  • 作者建议验证一种有效且安全的药物,并报告给药策略、镇静方案使用、辅助干预措施及预先定义的不良事件。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The use of sedative medications is commonplace in intensive care units (ICUs) and an invaluable clinical tool for the intensive care physician. Sedation for critically ill, mechanically ventilated patients provides an opportunity to reduce anxiety, discomfort as well as ventilator intolerance and dyssynchrony. Alpha-2 agonists in particular have become increasingly popular for use in the neurocritical care population due to their proposed effectiveness in facilitating examinations and procedures as well as reducing the need for adjunctive agents. However, there is a paucity of literature to assess the safety of their use in the neurocritically ill patients, a population that presents unique sensitivities and considerations for management of global and cerebral hemodynamics, agitation and facilitation of neurological assessments. This review assesses the safety and efficacy of alpha-2 agonists for non-procedural sedation in critically ill brain-injured patients on mechanical ventilation. In June 2016, we searched the EMBASE, MEDLINE and CENTRAL Cochrane Databases for randomized controlled trials, prospective and retrospective cohort studies examining neurocritically ill adult patients aged 18 years and older who are on mechanical ventilation and receiving alpha-2 agonists for non-procedural sedation. Primary outcomes of interest include mean arterial pressure (MAP), intracranial pressure (ICP), and cerebral perfusion pressure (CPP). Secondary outcomes include adverse events, duration of mechanical ventilation, 30-day mortality, ICU length of stay, incidence of delirium, and quality of sedation. We identified 17 studies for inclusion, all reporting on dexmedetomidine use, only 7 of which reported on our primary outcomes of interest. We found mixed results with regard to statistically significant changes in ICP, CPP, and MAP but did not find evidence of severe hemodynamic disturbances. However, the studies are notably limited by lack of reporting on sedative and hemodynamic adjuncts. Based on the limited available data, dexmedetomidine does not appear to result in severe, uncompensated hemodynamic disturbances (cerebral or systemic). The validation of an effective and safe agent with reporting of dosing strategy, sedation protocol use, co-interventions administered, and a priori defined adverse events is recommended.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Tran A, Blinder H, Hutton B, et al. A Systematic Review of Alpha-2 Agonists for Sedation in Mechanically Ventilated Neurocritical Care Patients. Neurocrit Care. 2018. PMID: 28547318. doi:10.1007/s12028-017-0388-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。